Table 1 Study population characteristics.
Levodopa-naive (Brazil) n = 49 | Levodopa+ n = 150 | Levodopa+ (Netherlands) n = 75 | Levodopa+ (Brazil) n = 75 | |
|---|---|---|---|---|
Age (years) | 65 [42–90] | 66 [33–93] | 69 [51–93] | 64 [33–91] |
Sex (M/F) | 30/19 | 107/43 | 58/17 | 49/26 |
Time since onset of motor symptoms (years) | 6.5* [5–20] | 7.7* [5–22] | 7.5 [5–16] | 7.8 [5–22] |
Time since diagnosis (years) | 4.0* [0.1–9] | 6.1* [2–11] | 6.1 [2–11] | 6.1 [5–11] |
Duration levodopa treatment (years) | N/A | 5.6 [2–10] | 5.6 [2–10] | 5.6 [3–10] |
Duration dopaminergic treatment (years) | N/A | 5.9 [2–10] | 5.8 [2–10] | 5.9 [3–10] |
Exposed to dopamine agonists (n, %) | N/A | 76 [51%] | 26 [35%] | 50 [67%] |
Levodopa equivalent dosage (g) | N/A | 0.79 [0.1–2.1] | 0.74 [0.1–1.1] | 0.84 [0.2–2.1] |
Cumulative lifetime levodopa exposure (g) | N/A | 727 [128–4122] | 888 [165–2732] | 567 [128–4122] |
MDS-UPDRS part III [0–136] | 30* [12–58] | 37* [12–79] | 38 [12–79] | 36 [12–66] |
Frontal Assessment Battery [0–18] | 15 [9–18] | 15 [9–18] | 16 [9–18] | 15 [8–18] |
Home assessment (n, %) | 12* [24%] | 81* [54%] | 75 [100%] | 6 [8%] |
